Loading…
Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib
Background No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs. Hypothesis/Objective To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in...
Saved in:
| Published in: | Journal of veterinary internal medicine 2018-11, Vol.32 (6), p.2061-2068 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3 |
| container_end_page | 2068 |
| container_issue | 6 |
| container_start_page | 2061 |
| container_title | Journal of veterinary internal medicine |
| container_volume | 32 |
| creator | Kovac, Rachel L. Ballash, Gregory Fenger, Joelle London, Cheryl Warry, Emma |
| description | Background
No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs.
Hypothesis/Objective
To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in dogs being treated with toceranib phosphate, can predict the onset of GI toxicosis. We hypothesize that an increase in CK18 concentrations will be detected before the development of GI toxicosis in dogs treated with toceranib phosphate.
Animals
Twenty healthy client‐owned dogs and 25 client‐owned dogs with surgically excised mast cell tumor (MCT).
Methods
Prospective cohort study. Dogs were treated with toceranib (2.75 mg/kg PO q48h). Plasma was collected weekly for 4 weeks. Plasma CK18 concentration was measured on days 0, 7, 14, 21, and 28. vascular endothelial growth factor was measured on days 0 and 28.
Results
Mean plasma CK18 concentration on day 0 in dogs with MCT was not significantly different than healthy controls (313.5 ± 592.8 pg/mL, 119.7 ± 76.9 pg/mL, mean ± SD P = 0.27). Mean plasma CK18 concentration decreased by 98.69 pg/mL from day 0 to day 28 (P |
| doi_str_mv | 10.1111/jvim.15326 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6271317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2189560539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhq2Kii6FSx8A-YiQ0nri2NlckFBFoahVOQBXy3HGi0tiFzubsid4hD5jn6Re0lZwwRdLns__zD8_IQfADiGfo8vJDYcgeCl3yAIa3hQga_mELNiygULKiu2RZyldMlYKIeqnZI8zLnjTlAvy61Ov06Cp2YzhO0Y9On_7-waW1ARv0I_bl-AT1Yn64J2fdHIT0taFQcf8gQZLUcd-Q1c6jTE4P2LKIrqnY_jpTEguUedpF1aJRjToJudXuWZyM-_a52TX6j7hi_t7n3w5eff5-ENxdvH-9PjtWWEqwWVhTWOhs2DaTtYWasxuAWRnjah0DVCJjtWilRUHieUSGULJK0Am0DIpW75P3sy6V-t2wG621qur6LKPjQraqX8r3n1TqzApWdbAoc4Cr-4FYvixzh7V4JLBvtcewzqpEpaNkCyvNaOvZ9TEkFJE-9gGmNompraJqT-JZfjl34M9og8RZQBm4Nr1uPmPlPr49fR8Fr0DO9Smug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189560539</pqid></control><display><type>article</type><title>Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>Kovac, Rachel L. ; Ballash, Gregory ; Fenger, Joelle ; London, Cheryl ; Warry, Emma</creator><creatorcontrib>Kovac, Rachel L. ; Ballash, Gregory ; Fenger, Joelle ; London, Cheryl ; Warry, Emma</creatorcontrib><description>Background
No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs.
Hypothesis/Objective
To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in dogs being treated with toceranib phosphate, can predict the onset of GI toxicosis. We hypothesize that an increase in CK18 concentrations will be detected before the development of GI toxicosis in dogs treated with toceranib phosphate.
Animals
Twenty healthy client‐owned dogs and 25 client‐owned dogs with surgically excised mast cell tumor (MCT).
Methods
Prospective cohort study. Dogs were treated with toceranib (2.75 mg/kg PO q48h). Plasma was collected weekly for 4 weeks. Plasma CK18 concentration was measured on days 0, 7, 14, 21, and 28. vascular endothelial growth factor was measured on days 0 and 28.
Results
Mean plasma CK18 concentration on day 0 in dogs with MCT was not significantly different than healthy controls (313.5 ± 592.8 pg/mL, 119.7 ± 76.9 pg/mL, mean ± SD P = 0.27). Mean plasma CK18 concentration decreased by 98.69 pg/mL from day 0 to day 28 (P < 0.001). Plasma CK18 concentration was not a significant predictor of the development of signs of GI toxicosis.
Conclusions and Clinical Importance
Plasma CK18 concentration was not a clinically useful biomarker for the early detection of GI toxicosis secondary to toceranib administration in dogs with MCTs.</description><identifier>ISSN: 0891-6640</identifier><identifier>EISSN: 1939-1676</identifier><identifier>DOI: 10.1111/jvim.15326</identifier><identifier>PMID: 30353992</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animals ; Antineoplastic Agents - adverse effects ; biomarkers ; Biomarkers - blood ; cancer ; canine ; Case-Control Studies ; chemotherapy ; cohort studies ; Dog Diseases - blood ; Dog Diseases - chemically induced ; Dog Diseases - diagnosis ; Dog Diseases - drug therapy ; Dogs ; Female ; Gastrointestinal Diseases - blood ; Gastrointestinal Diseases - chemically induced ; Gastrointestinal Diseases - diagnosis ; Gastrointestinal Diseases - veterinary ; gastrointestinal system ; Indoles - adverse effects ; Keratin-18 - blood ; Male ; mast cell tumor ; mast cells ; Mastocytosis - drug therapy ; Mastocytosis - veterinary ; phosphates ; poisoning ; Prospective Studies ; Pyrroles - adverse effects ; SMALL ANIMAL ; tyrosine kinase inhibitor ; Vascular Endothelial Growth Factor A - blood ; vascular endothelial growth factors ; veterinary medicine</subject><ispartof>Journal of veterinary internal medicine, 2018-11, Vol.32 (6), p.2061-2068</ispartof><rights>2018 The Authors. published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</rights><rights>2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3</citedby><cites>FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3</cites><orcidid>0000-0002-6493-5919</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271317/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271317/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,27924,27925,37013,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30353992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovac, Rachel L.</creatorcontrib><creatorcontrib>Ballash, Gregory</creatorcontrib><creatorcontrib>Fenger, Joelle</creatorcontrib><creatorcontrib>London, Cheryl</creatorcontrib><creatorcontrib>Warry, Emma</creatorcontrib><title>Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib</title><title>Journal of veterinary internal medicine</title><addtitle>J Vet Intern Med</addtitle><description>Background
No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs.
Hypothesis/Objective
To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in dogs being treated with toceranib phosphate, can predict the onset of GI toxicosis. We hypothesize that an increase in CK18 concentrations will be detected before the development of GI toxicosis in dogs treated with toceranib phosphate.
Animals
Twenty healthy client‐owned dogs and 25 client‐owned dogs with surgically excised mast cell tumor (MCT).
Methods
Prospective cohort study. Dogs were treated with toceranib (2.75 mg/kg PO q48h). Plasma was collected weekly for 4 weeks. Plasma CK18 concentration was measured on days 0, 7, 14, 21, and 28. vascular endothelial growth factor was measured on days 0 and 28.
Results
Mean plasma CK18 concentration on day 0 in dogs with MCT was not significantly different than healthy controls (313.5 ± 592.8 pg/mL, 119.7 ± 76.9 pg/mL, mean ± SD P = 0.27). Mean plasma CK18 concentration decreased by 98.69 pg/mL from day 0 to day 28 (P < 0.001). Plasma CK18 concentration was not a significant predictor of the development of signs of GI toxicosis.
Conclusions and Clinical Importance
Plasma CK18 concentration was not a clinically useful biomarker for the early detection of GI toxicosis secondary to toceranib administration in dogs with MCTs.</description><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>biomarkers</subject><subject>Biomarkers - blood</subject><subject>cancer</subject><subject>canine</subject><subject>Case-Control Studies</subject><subject>chemotherapy</subject><subject>cohort studies</subject><subject>Dog Diseases - blood</subject><subject>Dog Diseases - chemically induced</subject><subject>Dog Diseases - diagnosis</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Female</subject><subject>Gastrointestinal Diseases - blood</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Gastrointestinal Diseases - diagnosis</subject><subject>Gastrointestinal Diseases - veterinary</subject><subject>gastrointestinal system</subject><subject>Indoles - adverse effects</subject><subject>Keratin-18 - blood</subject><subject>Male</subject><subject>mast cell tumor</subject><subject>mast cells</subject><subject>Mastocytosis - drug therapy</subject><subject>Mastocytosis - veterinary</subject><subject>phosphates</subject><subject>poisoning</subject><subject>Prospective Studies</subject><subject>Pyrroles - adverse effects</subject><subject>SMALL ANIMAL</subject><subject>tyrosine kinase inhibitor</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>vascular endothelial growth factors</subject><subject>veterinary medicine</subject><issn>0891-6640</issn><issn>1939-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp9kcFu1DAQhq2Kii6FSx8A-YiQ0nri2NlckFBFoahVOQBXy3HGi0tiFzubsid4hD5jn6Re0lZwwRdLns__zD8_IQfADiGfo8vJDYcgeCl3yAIa3hQga_mELNiygULKiu2RZyldMlYKIeqnZI8zLnjTlAvy61Ov06Cp2YzhO0Y9On_7-waW1ARv0I_bl-AT1Yn64J2fdHIT0taFQcf8gQZLUcd-Q1c6jTE4P2LKIrqnY_jpTEguUedpF1aJRjToJudXuWZyM-_a52TX6j7hi_t7n3w5eff5-ENxdvH-9PjtWWEqwWVhTWOhs2DaTtYWasxuAWRnjah0DVCJjtWilRUHieUSGULJK0Am0DIpW75P3sy6V-t2wG621qur6LKPjQraqX8r3n1TqzApWdbAoc4Cr-4FYvixzh7V4JLBvtcewzqpEpaNkCyvNaOvZ9TEkFJE-9gGmNompraJqT-JZfjl34M9og8RZQBm4Nr1uPmPlPr49fR8Fr0DO9Smug</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Kovac, Rachel L.</creator><creator>Ballash, Gregory</creator><creator>Fenger, Joelle</creator><creator>London, Cheryl</creator><creator>Warry, Emma</creator><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6493-5919</orcidid></search><sort><creationdate>201811</creationdate><title>Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib</title><author>Kovac, Rachel L. ; Ballash, Gregory ; Fenger, Joelle ; London, Cheryl ; Warry, Emma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>biomarkers</topic><topic>Biomarkers - blood</topic><topic>cancer</topic><topic>canine</topic><topic>Case-Control Studies</topic><topic>chemotherapy</topic><topic>cohort studies</topic><topic>Dog Diseases - blood</topic><topic>Dog Diseases - chemically induced</topic><topic>Dog Diseases - diagnosis</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Female</topic><topic>Gastrointestinal Diseases - blood</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Gastrointestinal Diseases - diagnosis</topic><topic>Gastrointestinal Diseases - veterinary</topic><topic>gastrointestinal system</topic><topic>Indoles - adverse effects</topic><topic>Keratin-18 - blood</topic><topic>Male</topic><topic>mast cell tumor</topic><topic>mast cells</topic><topic>Mastocytosis - drug therapy</topic><topic>Mastocytosis - veterinary</topic><topic>phosphates</topic><topic>poisoning</topic><topic>Prospective Studies</topic><topic>Pyrroles - adverse effects</topic><topic>SMALL ANIMAL</topic><topic>tyrosine kinase inhibitor</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>vascular endothelial growth factors</topic><topic>veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovac, Rachel L.</creatorcontrib><creatorcontrib>Ballash, Gregory</creatorcontrib><creatorcontrib>Fenger, Joelle</creatorcontrib><creatorcontrib>London, Cheryl</creatorcontrib><creatorcontrib>Warry, Emma</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Online Library Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of veterinary internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovac, Rachel L.</au><au>Ballash, Gregory</au><au>Fenger, Joelle</au><au>London, Cheryl</au><au>Warry, Emma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib</atitle><jtitle>Journal of veterinary internal medicine</jtitle><addtitle>J Vet Intern Med</addtitle><date>2018-11</date><risdate>2018</risdate><volume>32</volume><issue>6</issue><spage>2061</spage><epage>2068</epage><pages>2061-2068</pages><issn>0891-6640</issn><eissn>1939-1676</eissn><abstract>Background
No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs.
Hypothesis/Objective
To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in dogs being treated with toceranib phosphate, can predict the onset of GI toxicosis. We hypothesize that an increase in CK18 concentrations will be detected before the development of GI toxicosis in dogs treated with toceranib phosphate.
Animals
Twenty healthy client‐owned dogs and 25 client‐owned dogs with surgically excised mast cell tumor (MCT).
Methods
Prospective cohort study. Dogs were treated with toceranib (2.75 mg/kg PO q48h). Plasma was collected weekly for 4 weeks. Plasma CK18 concentration was measured on days 0, 7, 14, 21, and 28. vascular endothelial growth factor was measured on days 0 and 28.
Results
Mean plasma CK18 concentration on day 0 in dogs with MCT was not significantly different than healthy controls (313.5 ± 592.8 pg/mL, 119.7 ± 76.9 pg/mL, mean ± SD P = 0.27). Mean plasma CK18 concentration decreased by 98.69 pg/mL from day 0 to day 28 (P < 0.001). Plasma CK18 concentration was not a significant predictor of the development of signs of GI toxicosis.
Conclusions and Clinical Importance
Plasma CK18 concentration was not a clinically useful biomarker for the early detection of GI toxicosis secondary to toceranib administration in dogs with MCTs.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30353992</pmid><doi>10.1111/jvim.15326</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6493-5919</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-6640 |
| ispartof | Journal of veterinary internal medicine, 2018-11, Vol.32 (6), p.2061-2068 |
| issn | 0891-6640 1939-1676 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6271317 |
| source | PubMed Central (Open Access); Publicly Available Content Database; Wiley Open Access |
| subjects | Animals Antineoplastic Agents - adverse effects biomarkers Biomarkers - blood cancer canine Case-Control Studies chemotherapy cohort studies Dog Diseases - blood Dog Diseases - chemically induced Dog Diseases - diagnosis Dog Diseases - drug therapy Dogs Female Gastrointestinal Diseases - blood Gastrointestinal Diseases - chemically induced Gastrointestinal Diseases - diagnosis Gastrointestinal Diseases - veterinary gastrointestinal system Indoles - adverse effects Keratin-18 - blood Male mast cell tumor mast cells Mastocytosis - drug therapy Mastocytosis - veterinary phosphates poisoning Prospective Studies Pyrroles - adverse effects SMALL ANIMAL tyrosine kinase inhibitor Vascular Endothelial Growth Factor A - blood vascular endothelial growth factors veterinary medicine |
| title | Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20cytokeratin%E2%80%9018%20concentrations%20as%20noninvasive%20biomarker%20of%20early%20gastrointestinal%20toxicosis%20in%20dogs%20receiving%20toceranib&rft.jtitle=Journal%20of%20veterinary%20internal%20medicine&rft.au=Kovac,%20Rachel%20L.&rft.date=2018-11&rft.volume=32&rft.issue=6&rft.spage=2061&rft.epage=2068&rft.pages=2061-2068&rft.issn=0891-6640&rft.eissn=1939-1676&rft_id=info:doi/10.1111/jvim.15326&rft_dat=%3Cproquest_pubme%3E2189560539%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4536-fc9f1df1cbd67f17e532116dfc54a71145d075b64316e28e0e12341e05ef066b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2189560539&rft_id=info:pmid/30353992&rfr_iscdi=true |